Skip to main content

Advertisement

SpringerLink
Log in

Efficacy of low-dose tacrolimus added to methotrexate in patients with rheumatoid arthritis in Japan: a retrospective study

  • Original Article
  • Published:
Modern Rheumatology

An Erratum to this article was published on 31 December 2008

Abstract

The aim of this study was to assess if low-dose tacrolimus is efficacious for the treatment of rheumatoid arthritis (RA) when combined with methotrexate (MTX). The clinical courses of 32 RA patients who received tacrolimus plus MTX were analyzed retrospectively. Disease activity and clinical response were evaluated by DAS28 (disease activity score of 28 joints) and EULAR (European League Against Rheumatism) response criteria. Tacrolimus was started at 1 mg/day in five patients, 1.5 mg/day in 24 patients, and three mg/day in 3 patients. At six months, tacrolimus was continued at 1–2 mg/day in 27 of 32 patients, but was discontinued in five cases who showed no or inadequate response. Of the 32 patients, 47% were evaluated as having a moderate or good response at one month of tacrolimus therapy, and 72% at six months. No serious adverse events were observed. Our results suggest that the addition of tacrolimus at low dose to MTX for the treatment of patients with moderately active RA appears to be highly efficacious. Further studies are required for the appropriate use of this expensive immunosuppressant in the treatment of RA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Kitahara K, Kawai S. Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2007;19:238–45.

    Article  PubMed  CAS  Google Scholar 

  2. Kondo H, Abe T, Hashimoto H, Uchida S, Irimajiri S, Hara M, et al. Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study. J Rheumatol. 2004;31:243–51.

    PubMed  CAS  Google Scholar 

  3. Kawai S, Hashimoto H, Kondo H, Murayama T, Kiuchi T, Abe T. Comparison of tacrolimus and mizoribine in a randomized, double-blind controlled study in patients with rheumatoid arthritis. J Rheumatol. 2006;33:2153–61.

    PubMed  CAS  Google Scholar 

  4. Furst DE, Saag K, Fleischmann MR, Sherrer Y, Block JA, Schnitzer T, et al. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. Arthritis Rheum. 2002;46:2020–8.

    Article  PubMed  CAS  Google Scholar 

  5. Yocum DE, Furst DE, Kaine JL, Baldassare AR, Stevenson JT, Borton MA, et al. Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial. Arthritis Rheum. 2003;48:3328–37.

    Article  PubMed  CAS  Google Scholar 

  6. Kremer JM, Habros JS, Kolba KS, Kaine JL, Borton MA, Mengle-Gaw LJ, et al. Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study. Arthritis Rheum. 2003;48:2763–8.

    Article  PubMed  CAS  Google Scholar 

  7. Arnett F, Edworthy S, Bloch D, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.

    Article  PubMed  CAS  Google Scholar 

  8. DAS-score NL. Home of the DAS. http://www.das-score.nl/www.das-score.nl/. Accessed 27 March 2008.

  9. Matsui T, Kuga Y, Kaneko A, Nishino J, Eto Y, Chiba N, et al. Disease Activity Score 28 (DAS28) using CRP underestimates the disease activity and overestimates the EULAR response criteria compared with DAS28 using ESR in a large observational cohort of rheumatoid arthritis patients in Japan. Ann Rheum Dis. 2007;66:1221–6.

    Article  PubMed  CAS  Google Scholar 

  10. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Comparison of Disease Activity Score (DAS)28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis. 2007;66:407–9.

    Article  PubMed  CAS  Google Scholar 

  11. Yamanaka H, Tanaka Y, Sekiguchi N, Inoue E, Saito K, Kameda H, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol. 2007;17:28–32.

    Article  PubMed  CAS  Google Scholar 

  12. Miyasaka N, Takeuchi T, Eguchi K. Guidelines for the proper use of etanercept in Japan. Mod Rheumatol. 2006;16:63–7.

    Article  PubMed  CAS  Google Scholar 

  13. Miyasaka N, Takeuchi T, Eguchi K. Proposed Japanese guidelines for the use of infliximab for rheumatoid arthritis. Mod Rheumatol. 2005;15:4–8.

    Article  PubMed  CAS  Google Scholar 

  14. Kawai S, Yamamoto K. Safety of tacrolimus, an immunosuppressive agent, in the treatment of rheumatoid arthritis in elderly patients. Rheumatology. 2006;45:441–4.

    Article  PubMed  CAS  Google Scholar 

  15. Azuma T, Oishi M, Takei M, Sawada S. Tacrolimus-related nocturnal myoclonus of the lower limbs in elderly patients with rheumatoid arthritis. Mod Rheumatol. 2007;17:247–50.

    Article  PubMed  Google Scholar 

  16. Tsujimura S, Saito K, Nawata M, Nakayamada S, Tanaka Y. Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis. Ann Rheum Dis. 2008;67:380–8.

    Article  PubMed  CAS  Google Scholar 

  17. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993;268:6077–80.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We thank Dr. Takashi Hayashi (Sayo Central Hospital) for providing the data. The authors have no conflicts of interest to disclose.

Author information

Authors and Affiliations

  1. Division of Nephrology and Rheumatology, Department of Internal Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama, 701-0192, Japan

    Yoshitaka Morita, Yumi Sasae, Takeo Sakuta, Minoru Satoh, Tamaki Sasaki & Naoki Kashihara

Authors
  1. Yoshitaka Morita
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yumi Sasae
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takeo Sakuta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Minoru Satoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tamaki Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Naoki Kashihara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshitaka Morita.

Additional information

An erratum to this article can be found at http://dx.doi.org/10.1007/s10165-008-0148-7

About this article

Cite this article

Morita, Y., Sasae, Y., Sakuta, T. et al. Efficacy of low-dose tacrolimus added to methotrexate in patients with rheumatoid arthritis in Japan: a retrospective study. Mod Rheumatol 18, 379–384 (2008). https://doi.org/10.1007/s10165-008-0071-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10165-008-0071-y

Keywords

Search

Navigation